CareLit Fachartikel

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

DP Carbone, D Morgensztern, S Le Moulec, R Santana-Davila, N Ready, CL Hann, BS Glisson, A Dowlati, CM Rudin, S Lally, S Yalamanchili, J Wolf, R Govindan, B Besse · Pneumologie · 2019 · Heft S 01 S 01

Dokument
1194751
CareLit-ID
Jahr
2019
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
DP Carbone, D Morgensztern, S Le Moulec, R Santana-Davila, N Ready, CL Hann, BS Glisson, A Dowlati, CM Rudin, S Lally, S Yalamanchili, J Wolf, R Govindan, B Besse
Ausgabe
Heft S 01 S 01 / 2019
Jahrgang 73
Seiten
–
Erschienen: 2019-03-01 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0039-1678065

Zusammenfassung

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

Schlagworte

Efficacy Safety Rovalpituzumab Tesirine Patients Dll3-Expressing Small Cancer Results Phase Trinity Study Pneumologie